CMPX
Price
$0.83Alerts
Change
-$0.01 (-1.19%)
Updated
Nov 11 closing price
Capitalization
136.65M
106 days until earnings call
Intraday BUY SELL Signals
XNCR
Price
$39.97Alerts
Change
+$0.58 (+1.47%)
Updated
Nov 11 closing price
Capitalization
2.66B
104 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CMPX vs XNCR

CMPX vs XNCR Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CMPX vs. XNCR commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMPX is a Buy and XNCR is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CMPX with price predictions
Nov 11, 2026

CMPX in +10.44% Uptrend, rising for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CMPX advanced for three days, in 229 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CMPX's RSI Oscillator exited the oversold zone, 31 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CMPX as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.

The Moving Average Convergence Divergence (MACD) for CMPX just turned positive on October 09, 2026. Looking at past instances where CMPX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

CMPX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CMPX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.823) is normal, around the industry mean (3.498). P/E Ratio (-1.946) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for XNCR with price predictions
Nov 11, 2026

XNCR in upward trend: price rose above 50-day moving average on October 26, 2026

XNCR moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend. In 25 of 32 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XNCR as a result. In 49 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for XNCR just turned positive on October 21, 2026. Looking at past instances where XNCR's MACD turned positive, the stock continued to rise in 32 of 47 cases over the following month. The odds of a continued upward trend are 68%.

The 10-day moving average for XNCR crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where XNCR advanced for three days, in 190 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XNCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

XNCR broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XNCR entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.282) is normal, around the industry mean (3.498). P/E Ratio (-16.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.740) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (16.949) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. XNCR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XNCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
XNCR: Fundamental Ratings
XNCR
OUTLOOK RATING
1..100
45
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CMPXXNCR
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
72%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
65%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 1 day ago
68%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 29 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CMPX: $0.83 vs. XNCR: $39.97)
Brand notoriety: CMPX and XNCR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMPX: 28% vs. XNCR: 74%
Market capitalization -- CMPX: $136.65M vs. XNCR: $2.66B
CMPX [@Biotechnology] is valued at $136.65M. XNCR’s [@Biotechnology] market capitalization is $2.66B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMPX’s FA Score shows that 1 FA rating(s) are green while XNCR’s FA Score has 1 green FA rating(s).

  • CMPX’s FA Score: 1 green, 4 red.
  • XNCR’s FA Score: 1 green, 4 red.
According to our system of comparison, XNCR is a better buy in the long-term than CMPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMPX’s TA Score shows that 4 TA indicator(s) are bullish while XNCR’s TA Score has 5 bullish TA indicator(s).

  • CMPX’s TA Score: 4 bullish, 4 bearish.
  • XNCR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CMPX and XNCR are a good buy in the short-term.

Price Growth

CMPX (@Biotechnology) experienced а +8.85% price change this week, while XNCR (@Biotechnology) price change was +14.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

CMPX is expected to report earnings on Feb 26, 2027.

XNCR is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CMPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMPX has been loosely correlated with VCYT. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CMPX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMPX
1D Price
Change %
CMPX100%
-0.93%
VCYT - CMPX
37%
Loosely correlated
+4.36%
SMMT - CMPX
35%
Loosely correlated
-6.67%
MIRM - CMPX
34%
Loosely correlated
+0.20%
VIR - CMPX
34%
Loosely correlated
-0.15%
XNCR - CMPX
34%
Loosely correlated
+1.47%
More

XNCR and

Correlation & Price change

A.I.dvisor indicates that over the last year, XNCR has been loosely correlated with KURA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if XNCR jumps, then KURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XNCR
1D Price
Change %
XNCR100%
+1.47%
KURA - XNCR
53%
Loosely correlated
+2.11%
VCYT - XNCR
52%
Loosely correlated
+4.36%
DYN - XNCR
52%
Loosely correlated
+0.39%
VIR - XNCR
49%
Loosely correlated
-0.15%
ORKA - XNCR
48%
Loosely correlated
-2.13%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CVRT42.600.80
+1.93%
Calamos Convertible Equity Alternative ETF (CVRT)
CCNR37.210.32
+0.87%
ALPS CoreCommodity Natural Resources ETF (CCNR)
AVOS27.120.17
+0.62%
Avos Global Equities ETF (AVOS)
BSVO28.820.16
+0.56%
EA Bridgeway Omni Small-Cap Value ETF (BSVO)
BAIG20.22N/A
N/A
Leverage Shares 2X Long Bbai Daily ETF